Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pharm |
RCV001787323 | SCV000268158 | drug response | peginterferon alfa-2b and ribavirin response - Toxicity | 2021-03-24 | reviewed by expert panel | curation | PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. |
Labcorp Genetics |
RCV000015867 | SCV001726918 | benign | Inosine triphosphatase deficiency | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001711071 | SCV001939337 | benign | not provided | 2021-05-04 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 17113761, 22060550, 22613675, 19914375, 24621321, 23528839, 19631656, 25525159, 22939045, 20173735, 21659334, 19682085, 23547827, 20547162, 20637204, 12384777, 27703193, 26394463, 30106365, 19579612) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001804735 | SCV002051024 | likely benign | not specified | 2021-12-10 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000015867 | SCV000036134 | affects | Inosine triphosphatase deficiency | 2009-09-25 | no assertion criteria provided | literature only |